Last reviewed · How we verify
Positive control vaccine 1
Positive control vaccine 1 is a vaccine Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently in Phase 3 development for Positive control comparator in phase 3 clinical trials (specific indication not disclosed).
A positive control vaccine designed to elicit immune responses by presenting antigenic material to stimulate adaptive immunity.
A positive control vaccine designed to elicit immune responses by presenting antigenic material to stimulate adaptive immunity. Used for Positive control comparator in phase 3 clinical trials (specific indication not disclosed).
At a glance
| Generic name | Positive control vaccine 1 |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a positive control vaccine, this agent is formulated to reliably trigger both humoral and cellular immune responses, serving as a reference standard in clinical trials. Positive control vaccines are used to validate trial methodology and demonstrate that the study population is capable of mounting appropriate immune responses. The specific antigenic composition and delivery mechanism are not publicly detailed.
Approved indications
- Positive control comparator in phase 3 clinical trials (specific indication not disclosed)
Common side effects
- Injection site reactions
- Fever
- Myalgia
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104 (PHASE1)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Positive control vaccine 1 CI brief — competitive landscape report
- Positive control vaccine 1 updates RSS · CI watch RSS
- Jiangsu Province Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about Positive control vaccine 1
What is Positive control vaccine 1?
How does Positive control vaccine 1 work?
What is Positive control vaccine 1 used for?
Who makes Positive control vaccine 1?
What drug class is Positive control vaccine 1 in?
What development phase is Positive control vaccine 1 in?
What are the side effects of Positive control vaccine 1?
Related
- Drug class: All vaccine drugs
- Manufacturer: Jiangsu Province Centers for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Positive control comparator in phase 3 clinical trials (specific indication not disclosed)
- Compare: Positive control vaccine 1 vs similar drugs
- Pricing: Positive control vaccine 1 cost, discount & access